Advertisement

Topics

Latest "Antikor Biopharma Limited" News Stories

14:35 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Antikor Biopharma Limited" found in our extensive news archives from over 250 global news sources.

More Information about Antikor Biopharma Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Antikor Biopharma Limited for you to read. Along with our medical data and news we also list Antikor Biopharma Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Antikor Biopharma Limited Companies for you to search.

Showing "Antikor Biopharma Limited" News Articles 1–25 of 2,200+

Friday 15th February 2019

Biopharma companies are preparing for #climatechange. https://buff.ly/2SUdP6E 

Biopharma companies are preparing for #climatechange. https://buff.ly/2SUdP6E 


Avapritinib receives Phase III clinical trial approval for GIST in China

SUZHOU, China, Feb. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone") today announced that the National Medical Products Administration (NMPA) recently approved a Phase III clinical trial in China for its partnered drug candidate avapritinib as a third-line treatment against KIT-driven gastrointestinal stromal tumors (GIST). The study will be part of the global VOYAGER Phase II...

Kiadis Pharma Notice of Extraordinary General Meeting of Shareholders

                                                                  Amsterdam, The Netherlands, 15 February 2019 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces that it has convened an extraor...


Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI...   

Hurricanes, power outages, floods, droughts, forest fires — it's all a risk for biopharma companies. Here's how the industry is preparing for climate change. https://buff.ly/2SBxIAd 

Hurricanes, power outages, floods, droughts, forest fires — it's all a risk for biopharma companies. Here's how the industry is preparing for climate change. https://buff.ly/2SBxIAd 

Hurricanes, droughts, and wildfires: How biopharma is girding for climate change

Hurricanes, power outages, floods, droughts, forest fires — it's all a risk for biopharma companies. Here's how the industry is preparing for climate change.

Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML

Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech The post Vor Biopharma raises $42m to advance development of cell therapy product candidate for AML appeared first on Pharmaceutical Business review.

Vor Biopharma receives $42m funds to advance development of cell therapy product candidate for acute myeloid leukemia

Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research (NIBR), and Osage University Partners also participated in the round along with Vor Co-founder PureTech The post Vor Biopharma receives $42m funds to advance development of cell therapy product candidate for acute myeloid leukemia appeared first on Pharmaceutical Business review.

Herantis Pharma Plc is planning a directed share issue and prepares for a contemplated secondary listing on the First North Stockholm marketplace

Herantis Pharma Plc is planning a directed share issue to a limited number of investors and the company's directors and prepares for a contemplated secondary listing on the First North Stockholm marketplace Herantis Pharma Plc Company release 15 February 2019 at 9:00 am Not for publication or distribution, directly or indirectly, in or into Australia, South Africa, Hong Kong, Japa...

Thursday 14th February 2019

Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference

JERSEY, Channel Islands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, 2019 at 10:00 a.m. EST at the Lotte New York Palace Hotel, in New York, NY. ...

Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period

OCALA, Fla., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced that the subscription period for the rights offering has commenced. If exercising subscription rights through a broker, dealer, bank or...

#news #biotech Experimental Drug Blocks Development of Malignant Melanomas

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Experimental Drug Blocks Development of Malignant Melanomas .A promising experimental drug may prevent growth and spread of malignant melanomas having a mutation in the NRAS gene. from Drug … Continue reading →

#news #biotech Darwin’s rabbit helps to explain the fightback against myxomatosis

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Darwin’s rabbit helps to explain the fightback against myxomatosis .Nearly seventy years after myxomatosis decimated the rabbit populations of Australia, Britain and France, a new study reveals how … Continue reading →

#news #biotech Nimbus brings on Janssen discovery head as CSO with plans to expand its portfolio

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Nimbus brings on Janssen discovery head as CSO with plans to expand its portfolio .Digital drug miner Nimbus Therapeutics has brought on Janssen’s global head of lead discovery, … Continue reading →

#news #biotech Reprogramming pancreatic cells into insulin makers to treat diabetes

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Reprogramming pancreatic cells into insulin makers to treat diabetes .Scientists are keen to find methods for regenerating insulin-producing beta cells to treat diabetes. Now, researchers at the University … Continue reading →

J&J and Novartis back cancer geneticist’s start-up

Siddhartha Mukherjee’s Vor Biopharma raises $42m for leukaemia trials

Vor Biopharma raises $42M in Series A round to advance AML cell therapy toward clinic

5AM Ventures and RA Capital Management led the round. The company is developing hematopoietic stem cells engineered to be protected from targeted immunothe

#news #biotech Axovant sends off its small molecule team with an epilepsy drug and $100M in funding commitments

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Axovant sends off its small molecule team with an epilepsy drug and $100M in funding commitments .Axovant has spun off its small molecule team into a new company, … Continue reading →

Sartorius AG: Executive Board and Supervisory Board resolve dividend proposal of € 0.62 per preference share and € 0.61 per ordinary share

At today´s meeting, the Supervisory Board of Sartorius AG (FWB:SRT) approved the Executive Board’s recommendation to submit a proposal to the Annual General Shareholders’ Meeting on March 28, 2019, to pay dividends of 0.62 euro per preference share and 0.61 euro per ordinary share. Prior-year dividends were 0.51 euro and 0.50 euro per preference share...

Propanc at final stages of completing manufacturing steps to file first clinical trial application

Propanc Biopharma, Inc. (OTCQB: PPCB) CEO James Nathanielsz sat down with Proactive Investors at the BIO CEO and Investor Conference in New York. The biopharmaceutical company is developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers.

Tmunity Appoints Patrick Gray and Garry Nicholson to its Board of Directors as Independent Directors

Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced the appointments of Patrick Gray and Garry Nicholson to its Board of Directors, serving as independent directors effective immediately. “I am ...

Martin Åmark, CEO for Xbrane Biopharma AB, becomes Head of IR for the Company

Press release2019-02-14 Martin Åmark, CEO of Xbrane Biopharma AB ("Xbrane"), will as of today also be the Head of IR for Xbrane. The reason for this is that Xbrane's current Head of IR and CFO, Susanna Helgesen, will be on parental leave on a part-time basis for a period. During the parental leave, Susanna Helgesen will remain as CFO. The finance team has also bee...

Vor Biopharma Completes $42M Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia https://www.businesswire.com/news/home/20190213005927/en/Vor-Biopharma-Completes-42-Million-Series-Financing 

Vor Biopharma Completes $42M Series A Financing Round to Advance Lead Cell Therapy Product Candidate for the Treatment of Acute Myeloid Leukemia https://www.businesswire.com/news/home/20190213005927/en/Vor-Biopharma-Completes-42-Million-Series-Financing …

Feedback Medical appoints radiologist and NHS England Clinical Entrepreneur Fellow as CEO

Cambridge, UK, 14 February 2019 - Feedback plc (AIM: FDBK, "Feedback", or the “Company”), the specialist medical imaging technology company, announces that its operating subsidiary, Feedback Medical Ltd, has appointed Dr Tom Oakley as its Chief Executive Officer. A qualified clinical radiologist, Dr Oakley has significant experience of successfully launching healthcare pr...

AbbVie and Teneobio Link on Multiple Myeloma

US biopharma AbbVie has agreed a deal with Teneobio, a California-based biotech, to develop and commercialize an immunotherapeutic that targets B-cell maturation antigen (BCMA) for treating multiple myeloma, a type of blood cancer. Under the terms of the transaction, AbbVie will pay $90 million upfront to develop Teneobio’s TNB-383B, a bispecific antibody.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks